201 related articles for article (PubMed ID: 34133205)
1. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
Liu BP; Rosenberg M; Saverio P; Weon YC; Peters S; Ardellier FD; Boeckenhoff A; Endrikat J
AJR Am J Roentgenol; 2021 Nov; 217(5):1195-1205. PubMed ID: 34133205
[No Abstract] [Full Text] [Related]
2. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.
Anzalone N; Scarabino T; Venturi C; Cristaudo C; Tartaro A; Scotti G; Zimatore D; Floris R; Carriero A; Longo M; Cirillo M; Cova MA; Gatti S; Voth M; Colosimo C
Eur J Radiol; 2013 Jan; 82(1):139-45. PubMed ID: 21890295
[TBL] [Abstract][Full Text] [Related]
3. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study).
Maravilla KR; San-Juan D; Kim SJ; Elizondo-Riojas G; Fink JR; Escobar W; Bag A; Roberts DR; Hao J; Pitrou C; Tsiouris AJ; Herskovits E; Fiebach JB
AJNR Am J Neuroradiol; 2017 Sep; 38(9):1681-1688. PubMed ID: 28663267
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Kuhl C; Csőszi T; Piskorski W; Miszalski T; Lee JM; Otto PM
Radiology; 2023 Jul; 308(1):e222612. PubMed ID: 37462494
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.
Loevner LA; Kolumban B; Hutóczki G; Dziadziuszko K; Bereczki D; Bago A; Pichiecchio A
Invest Radiol; 2023 May; 58(5):307-313. PubMed ID: 36729404
[TBL] [Abstract][Full Text] [Related]
7. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
[TBL] [Abstract][Full Text] [Related]
8. MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
Saake M; Langner S; Schwenke C; Weibart M; Jansen O; Hosten N; Doerfler A
Eur Radiol; 2016 Mar; 26(3):820-8. PubMed ID: 26123410
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
11. Comparison of enhancement of the vestibular perilymph between gadoterate meglumine and gadobutrol at 3-Tesla in Meniere's disease.
Eliezer M; Poillon G; Gillibert A; Horion J; Cruypeninck Y; Gerardin E; Magne N; Attyé A
Diagn Interv Imaging; 2018 May; 99(5):271-277. PubMed ID: 29398574
[TBL] [Abstract][Full Text] [Related]
12. MR Angiography at 3 T of Peripheral Arterial Disease: A Randomized Prospective Comparison of Gadoterate Meglumine and Gadobutrol.
Loewe C; Arnaiz J; Krause D; Marti-Bonmati L; Haneder S; Kramer U;
AJR Am J Roentgenol; 2015 Jun; 204(6):1311-21. PubMed ID: 26001243
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T.
Attenberger UI; Runge VM; Morelli JN; Williams J; Jackson CB; Michaely HJ
J Magn Reson Imaging; 2010 Mar; 31(3):549-55. PubMed ID: 20187196
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of macroscopic and microscopic myocardial fibrosis by cardiac MR: intra-individual comparison of gadobutrol versus gadoterate meglumine.
Rahsepar AA; Ghasemiesfe A; Suwa K; Dolan RS; Shehata ML; Korell MJ; Naresh NK; Markl M; Collins JD; Carr JC
Eur Radiol; 2019 Aug; 29(8):4357-4367. PubMed ID: 30617490
[TBL] [Abstract][Full Text] [Related]
16. The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).
Vaneckova M; Herman M; Smith MP; Mechl M; Maravilla KR; Weichet J; Spampinato MV; Žižka J; Wippold FJ; Baima JJ; Babbel R; Bültmann E; Huang RY; Buhk JH; Bonafé A; Colosimo C; Lui S; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJNR Am J Neuroradiol; 2015 Sep; 36(9):1589-98. PubMed ID: 26185325
[TBL] [Abstract][Full Text] [Related]
17. Brain MRI with single-dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: comparison with 0.15 mmol/kg Gadoterate meglumine.
Kramer H; Runge VM; Naul LG; Loynachan AT; Reiser MF; Wintersperger BJ
AJR Am J Roentgenol; 2010 May; 194(5):1337-42. PubMed ID: 20410423
[TBL] [Abstract][Full Text] [Related]
18. Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose.
Kramer JH; Arnoldi E; François CJ; Wentland AL; Nikolaou K; Wintersperger BJ; Grist TM
Invest Radiol; 2013 Mar; 48(3):121-8. PubMed ID: 23211552
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol.
Lee CH; Vellayappan B; Taupitz M; Hamm B; Asbach P
Eur Radiol; 2019 Dec; 29(12):6982-6990. PubMed ID: 31264013
[TBL] [Abstract][Full Text] [Related]
20. A Japanese, Multicenter, Open-label, Phase 3 Study to Investigate the Safety and Efficacy of Gadobutrol for Contrast-enhanced MR Imaging of the Central Nervous System.
Tanaka A; Masumoto T; Yamada H; Kurauchi M; Breuer J
Magn Reson Med Sci; 2016; 15(2):227-36. PubMed ID: 26687097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
